Riskpilot← Back to searchSign inGet full accessVirotech AB
ABActiveOrg 5591787717Nubbgatan 5Engineering activities and related technical consultancy · NACE 7112Est. 20181 employees
Revenue 2024
SEK 2,8M
+1484% vs 2023
EBITDA margin
49.8%
+736% vs 2023
Equity ratio
61.8%
Financial strength
Net profit 2024
SEK 1,1M
+791% vs 2023
| Revenue | SEK 2,8M | +1484% |
| EBITDA | SEK 1,4M | +736% |
| Net profit | SEK 1,1M | +791% |
| Total assets | SEK 2,2M | +602% |
| Equity | SEK 1,3M | +472% |
| Employees | 1 | — |
Legal name
Virotech AB
Org number
5591787717
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
7 november 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva verksamhet inom montage av elektromekaniska produkter inom medicinteknik, framtagning av elektromekaniska prototyper inom medicinteknik och därmed förenlig verksamhet.
Address
Nubbgatan 5
Phone
+46709855687
Email
info@virotech.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 163 | 350 | 115 | 179 | 2 835 |
| Staff expenses | — | — | — | — | −833 |
| EBITDA | 146 | 280 | 58 | 169 | 1 412 |
| Depreciation & amort. | −10 | −5 | −5 | −11 | −13 |
| EBIT | 136 | 275 | 53 | 158 | 1 400 |
| Net financials | — | −1 | −1 | −1 | 5 |
| Profit before tax | 136 | 274 | 52 | 158 | 1 404 |
| Tax | −29 | −57 | −11 | −33 | −290 |
| Net profit | 107 | 217 | 41 | 125 | 1 114 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 294 | 397 | 168 | 311 | 2 183 |
| Equity | 202 | 269 | 110 | 236 | 1 350 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 92 | 128 | 58 | 75 | 833 |
| Total debt | 92 | 128 | 58 | 75 | 833 |
EBITDA margin
49.8%
This company
15.8%
Market median
+215% vs market
20202024
Equity ratio
61.8%
This company
38.2%
Market median
+62% vs market
20202024
Return on equity
82.5%
This company
18.4%
Market median
+348% vs market
20202024
Net profit margin
39.3%
This company
8.1%
Market median
+385% vs market
20202024
Asset turnover
1.30×
This company
1.12×
Market median
+16% vs market
20202024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Virotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Johan Henrik Röstlund | Deputy Board Member | 0 companies |
| Hue Kim Vien | Board of Directors | 0 companies |